Patent ID: RE44681

Claim:
A method of inhibiting growth of a cell from a smad4-deficient tumor that is smad4 deficient , comprising: (a) determining the level of expression of smad4 in a cell from said cancer smad4-deficient tumor ; and (b) treating a cancer cell that is deficient in smad4 expression the smad4-deficient tumor with one or more an Î±vÎ²6 antagonist antibody that selectively binds to the integrin Î±vÎ²6 in said cancer cell , wherein said one or more antibody is an antibody from produced by, or a humanized version of an antibody produced by, a hybridoma selected from the group consisting of 2A1 (deposited under ATCC Accession No. ATCC PTA-3896), 2E5 (deposited under ATCC Accession No. ATCC PTA-3897), 1A8 (deposited under ATCC Accession No. ATCC PTA-3647), 2B10 ( deposited under ATCC Accession No. ATCC PTA-3648), 2B1 ( deposited under ATCC Accession No. ATCC PTA-3646), 1G10 (deposited under ATCC Accession No. ATCC PTA-3898), 7G5 (deposited under ATCC Accession No. ATCC PTA-3899), 8G6 (deposited under ATCC Accession No. ATCC PTA-3645), and 3G9 (deposited under ATCC Accession No. ATCC PTA-3649), or a humanized version thereof wherein said treatment results in the growth inhibition of said cancer cell smad4-deficient tumor .